ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors

Wu, Ting-Ting; Guo, Qing-Qing; Chen, Zi-Li; Wang, Li-Li; Du, Yao; Chen, Rui; Mao, Yuan-Hu; Yang, Sheng-Gang; Huang, Jing; Wang, Jian-Ta; Wang, Ling; Tang, Lei*; Zhang, Ji-Quan*
European Journal of Medicinal Chemistry2020-10-15DOI: 10.1016/j.ejmech.2020.112637
26被引8阅读
引用收藏
分享

摘要

A series of novel substituted triazines bearing a benzimidazole scaffold were designed and synthesized based on the structures of known anti-cancer agents, namely gedatolisib and alpelisib. All the target compounds were screened for inhibitory activity against PI3K alpha and mTOR kinases. Notably, most analogs exhibited IC50 in the nanomolar range. Investigation of the isozyme selectivity indicated that the compounds exhibited remarkable inhibitory activity against PI3K delta, especially compound 19f showed an IC50 value of 2.3 nM for PI3K delta and moderate d delta-isozyme selectivity over other class I PI3K isoforms and mTOR (with IC50 values of 14.6, 34.0, 849.0 and 15.4 nM for PI3K alpha, beta, gamma and mTOR, respectively). An in vitro MTT assay was conducted to assess the antiproliferative and cytotoxic effects of the prepared analogs. It was revealed that the compounds displayed significant inhibitory activities against the HCT116 human colon cancer cell line. Compound 19i showed 4.7-fold higher potency than the positive control gedatolisib (0.3 vs. 1.4 mu M, IC50 values). Phosphoblot studies demonstrated that 19c and 19i could significantly suppress the PI3K/Akt/mTOR signaling pathway at 10 mu M. Moreover, analogs 19b, 19c and 19i displayed better stability in artificial gastric fluids than gedatolisib, while 19i was indicated not very stable in rat liver microsomes, and may occur phase I metabolic transformations.

学科与关键词

关键词
TriazinePhosphoinositide 3-kinaseMechanistic target of rapamycinStructure-activity relationshipSynthesis
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
European Journal of Medicinal Chemistry
发表日期
2020-10-15
卷期
第 204 卷
页码
112637
DOI
10.1016/j.ejmech.2020.112637
语言
MULTI-LANGUAGE
期刊收录
NSL.SCIE
期刊等级
1区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81703356, 81973241, 81502984, 81860627]; Fundamental Research Funds for the Central Universities [2018ZD37]; Guizhou Provincial Natural Science Foundation [[2020]1Z073]; Natural Science Foundation of Guangdong Province [2016A030310421, 2020A1515010548]; National Science Fundation of Health and Family planning Commission of Guizhou Province [gzwjkj2019-1-179]; Science Fundation of Guiyang [[2017]30-28]; Undergraduate Training Program for Innovation & Entrepreneurship of Guizhou Province [2018520355, 20195200128]

作者

  • W

    Wu, Ting-Ting (第一作者)

  • G

    Guo, Qing-Qing

查看全部 13 位作者收起作者
  • C

    Chen, Zi-Li

  • W

    Wang, Li-Li

  • D

    Du, Yao

  • C

    Chen, Rui

  • M

    Mao, Yuan-Hu

  • Y

    Yang, Sheng-Gang

  • H

    Huang, Jing

  • W

    Wang, Jian-Ta

  • W

    Wang, Ling

  • T

    Tang, Lei (通讯)

  • Z

    Zhang, Ji-Quan (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417